IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company focused on therapeutic eyecare, has announced the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic biopharmaceutical company and developer of IRX-101, an investigational ocular antiseptic with the potential to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy. The companies disclosed that the financial transaction included an upfront consideration of approximately $75 million, consisting of $37.5 million in cash and $37.5 million in Tarsus common stock, with potential approval and commercial milestone payments of up to $490 million.
“With Xdemvy, we demonstrated the importance of meaningful innovation in areas of eyecare that had previously been overlooked despite their significant impact on patients,” said Bobby Azamian, MD, Ph.D., chief executive officer and chairman of Tarsus. “We believe IRX-101 has the potential to do the same for patients with retinal disease who rely on repeated procedures to preserve their vision. By reducing the pain and ocular surface toxicity associated with current antiseptic approaches, IRX-101 has the potential to benefit both patients and physicians while also establishing an important foundation in retina as we continue building a leading eyecare company.”
More than 11 million intravitreal injections are performed in the United States each year, the vast majority of which rely on povidone-iodine as a pre-procedural antiseptic, the announcement stated. For many patients, povidone-iodine is associated with significant ocular surface toxicity, resulting in corneal damage and pain that can persist for days following treatment. Despite this, and despite being contraindicated in patients with iodine sensitivity, Tarsus said there have been no new FDA-approved ocular antiseptics in more than four decades.
IRX-101 is a stable aqueous chlorine dioxide solution that demonstrated, in a phase 2b/3 study, statistically significant reductions in post-procedural pain and corneal fluorescein staining (a measure of corneal surface damage) compared to povidone-iodine (Betadine), according to the announcement.
“IRX-101 was developed to improve the treatment experience for patients undergoing repeated retinal procedures,” said Stephen J. Smith, MD, chief executive officer and co-founder of iRenix Medical. “I am incredibly proud of what the iRenix team accomplished in advancing the program into late-stage clinical development and demonstrating its potential to meaningfully improve the patient experience. We believe Tarsus is the ideal company to take IRX-101 through the next stage of development and ultimately bring it to patients. Their track record of identifying important unmet needs in eyecare and successfully developing and commercializing innovative therapies gives us confidence in the future of the program.”
Patients with chronic retinal diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO)-related macular edema, and geographic atrophy (GA) frequently require treatment with intravitreal injections as often as every four weeks to preserve vision. Because treatment is ongoing and highly dependent on patient adherence, discomfort associated with povidone-iodine exposure—including post-procedural pain and corneal toxicity—can become a cumulative and recurring burden. This may affect a patient’s willingness to return for future treatments and disrupt continuity of care, the announcement said.
Based on data from a phase 2b/3 RELIEF trial and in alignment with feedback from the U.S. Food and Drug Administration, Tarsus said it plans to initiate a phase 3 study designed to evaluate the tolerability and safety of IRX-101 compared to povidone-iodine. The study is expected to begin enrolling in the first half of 2027 with results anticipated in 2028, the company advised.
